Table 1 |
|
| Patient Characteristics at the Time of Primary Diagnosis of Ovarian Cancer | |
| Patients (%) | |
| Total | 63 |
| Age | 58 years (range 21 – 81 years) |
| Tumor stage | |
| FIGO I-II | 13 (20.6) |
| FIGO III | 35 (55.6) |
| FIGO IV | 15 (23.8) |
| Lymph node metastasis | |
| N0 | 22 (34.9) |
| N1 | 20 (31.7) |
| Nx | 21 (33.3) |
| Tumor grading | |
| I - II | 31 (49.2) |
| III - IV | 32 (50.8) |
| Histologic subtype | |
| serous papillary | |
| subtype | 50 (79.4) |
| other subtypes | 13 (20.6) |
| Residual tumor | |
| macroscopic | |
| complete resection | 30 (47.6) |
| any residual tumor | 33 (52.4) |
| Survival | |
| OSa | 36.5 months (range 1 – 70 months) |
| Alive | 28 (44.4) |
| Dead | 34 (54.0) |
| DFSb | 12 months (range 6 – 48 months) |
| no relapse | 18 (28.6) |
| relapse | 45 (71.4) |
| Platinum Resistance | |
| Platinum sensitive 54 (85.7) | |
| Platinum resistant | 9 (14.3) |
| DTCc | |
| DTC prior to chemotherapy | |
| Positive | 27 (50.9) |
| Negative | 26 (49.1) |
| DTC after chemotherapy | |
| positive | 20 (50.0) |
| negative | 20 (50.0) |
aOS, overall survival.
bDFS, disease-free survival.
cDTC, disseminated tumor cells in BM.
Kuhlmann et al. BMC Cancer 2012 12:325 doi:10.1186/1471-2407-12-325
